Geode Capital Management
BOLT icon

Geode Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Geode Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.6K Sell
19,119
-9,672
-34% -$45.4K ﹤0.01% 4171
2026
Q1 		$116K Buy
28,791
+9,988
+53% +$52K ﹤0.01% 4095
2025
Q4 		$103K Buy
18,803
+270
+1% +$1.45K ﹤0.01% 4088
2025
Q3 		$98.6K Hold
18,533
– – ﹤0.01% 4135
2025
Q2 		$108K Sell
18,533
-223
-1% -$1.48K ﹤0.01% 4040
2025
Q1 		$150K Buy
18,756
+1,722
+10% +$16.5K ﹤0.01% 3926
2024
Q4 		$182K Sell
17,034
-587
-3% -$7.1K ﹤0.01% 3932
2024
Q3 		$228K Sell
17,621
-919
-5% -$12.7K ﹤0.01% 3863
2024
Q2 		$278K Buy
18,540
+1,162
+7% +$22.9K ﹤0.01% 3796
2024
Q1 		$487K Sell
17,378
-130
-0.7% -$3.01K ﹤0.01% 3627
2023
Q4 		$392K Sell
17,508
-529
-3% -$10.3K ﹤0.01% 3704
2023
Q3 		$375K Buy
18,037
+426
+2% +$10.4K ﹤0.01% 3713
2023
Q2 		$451K Buy
17,611
+8,711
+98% +$277K ﹤0.01% 3682
2023
Q1 		$247K Buy
8,900
+1,196
+16% +$35K ﹤0.01% 3942
2022
Q4 		$200K Buy
7,704
+593
+8% +$16.3K ﹤0.01% 4103
2022
Q3 		$210K Hold
7,111
– – ﹤0.01% 4182
2022
Q2 		$290K Sell
7,111
-9,224
-56% -$358K ﹤0.01% 4050
2022
Q1 		$895K Sell
16,335
-3,272
-17% -$220K ﹤0.01% 3669
2021
Q4 		$1.92M Buy
19,607
+2,351
+14% +$446K ﹤0.01% 3383
2021
Q3 		$4.37M Buy
17,256
+6,748
+64% +$1.91M ﹤0.01% 2988
2021
Q2 		$3.25M Buy
10,508
+15
+0.1% +$6.09K ﹤0.01% 3120
2021
Q1 		$6.91M Buy
+10,493
New +$6.83M ﹤0.01% 2612

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's BOLT Position: Q2 2026 in Review

Geode Capital Management reduced its Bolt Biotherapeutics (BOLT) stake by 34% in Q2 2026, selling an estimated $45.4K and leaving 19,119 shares worth $73.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4171.

Geode Capital Management first reported a position in BOLT in Q1 2021 and has held it in 22 quarters since. The position peaked at $6.91M in Q1 2021. 19 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • Geode Capital Management held 19,119 shares of Bolt Biotherapeutics worth $73.6K as of Q2 2026.
  • Geode Capital Management sold 9,672 Bolt Biotherapeutics shares in Q2 2026, an estimated $45.4K.
  • Bolt Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4171 holding.
  • Geode Capital Management first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
  • Geode Capital Management's Bolt Biotherapeutics position peaked at $6.91M in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.